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ABSTRACT 
 
Influenza A and B viruses are responsible for respiratory infections, representing globally 
seasonal threats to human health. The two viral types often co-circulate and influenza B plays 
an important role in the spread of infection. 
A 6-year retrospective surveillance study was conducted between 2010 and 2016 in two large 
administrative regions of Italy, located in the north (Liguria) and in the south (Sicily) of the 
country, in order to describe the burden and epidemiology of both B/Victoria and 
B/Yamagata lineages in different healthcare settings. 
Influenza B viruses were detected in five of six seasonal outbreaks, exceeding influenza A 
during the season 2012-2013. Most of influenza B infections were found in children aged ≤14 
years and significant differences were observed in the age-groups infected by the different 
lineages. B/Victoria strains prevailed in younger population than B/Yamagata, but also were 
more frequently found in the community setting. Conversely, B/Yamagata viruses were 
prevalent among hospitalized cases suggesting their potential role in the development of more 
severe disease. 
The relative proportions of viral lineages varied from year to year, resulting in different 
lineage-level mismatch for the B component of trivalent influenza vaccine. 
Our findings confirmed the need for continuous virological surveillance of seasonal 
epidemics and bring attention to the adoption of universal influenza immunization programme 
in the childhood. The use of tetravalent vaccine formulations may be useful to improve the 
prevention and control of the influenza burden in general population. 
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INTRODUCTION 
 
Influenza A and B are major causes of respiratory infections in human and contribute to 
increase morbidity and mortality globally [1-6]. The clinical presentation of influenza A 
seems to be comparable to that of influenza B [7,8]; this latter, like influenza A, can lead to 
severe complications and death in both paediatric and adult populations [9-11]. Despite 
similar clinical phenotypes, the two viral types appear considerably dissimilar in their 
propensity for genetic reassortment as a consequence of differences in the corresponding host 
reservoirs. 
In fact, influenza A viruses have been isolated from various species including humans and 
this have contributed to viral heterogeneity, generating various subtypes which have the 
potential to cause human pandemics [12]. 
Conversely, influenza B virus is supposed to have evolved almost exclusively as human 
pathogen and this has limited the generation of new strains by reassortment, leading to scarse 
pandemic potential, although its presence has been confirmed in throat swab obtained from 
seal [13,14], and detected in nasal swabs from domestic pigs by real-time reverse 
transcription PCR and sequencing [15]. 
Influenza B viruses are not formally classified into subtypes. However, two antigenically and 
genetically distinct major lineages are universally recognized, which evolved since 1983 from 
the first isolate B/Lee/40 [16], actually referring to B/Victoria/2/87 and B/Yamagata/16/88 
strains, henceforth termed the Victoria and Yamagata lineages, respectively. 
From a public health point of view, vaccination is the primary measure to prevent influenza 
and reduce its impact in the population. For decades, licensed trivalent seasonal influenza 
vaccines have contained two type A strains (A/H1N1 and A/H3N2) and one of the two known 
divergent influenza B lineages, which have also been shown to circulate simultaneously. In 
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this context, it has represented a challenge in terms of vaccine efficacy and effectiveness, 
because of the limited cross protection between the two influenza B lineages [17,18] and the 
degree of mismatch of seasonal vaccines in respect to circulating influenza B virus strains 
[19,20]. These factors make difficult the yearly production of influenza vaccines and force to 
continuously update the correct B component, determining an increasing interest in 
production of quadrivalent vaccines that include both antigenic variants of influenza B 
viruses. Nevertheless, the potential benefits afforded by these vaccines, in terms of reduced 
burden and outcomes of seasonal influenza illness, are still hampered by different reasons 
which prevent their adoption to a large-scale context. 
Data regarding the circulation in Italy of influenza B strains belonging to different lineages 
are quite sparse and limited [21-24]. The present retrospective surveillance study aimed to 
improve the knowledge of the burden and epidemiology of influenza B during annual 
outbreaks among patients with influenza-like illness (ILI) in either community or hospital 
contexts over the period 2010-2016. The mismatch ratio between seasonal circulating and 
vaccine included influenza B strains was also analysed. 
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RESULTS 
 
Epidemiology of influenza viruses between 2010 and 2016 
During the 6-year study period, influenza A and B viruses co-circulated in almost all seasonal 
epidemics, with the exclusion of the season 2011-2012 when influenza B was not detected at 
all in the regions included in the study. Influenza A strains exceeded influenza B in four 
seasons (2010-2011, 2013-2014, 2014-2015, and 2015-2016), with different timing of peak 
activity, while influenza B viruses significantly prevailed for most of the season 2012-2013 
(Figure 1). 
A total of 14,212 specimens were collected and laboratory tested from subjects with ILI 
symptoms (Table 1). Despite the natural fluctuation in ILI incidence rates reported in Italy 
between 2010 and 2016, the total number of respiratory samples collected in Liguria and 
Sicily, for influenza detection and genotyping, progressively increased year after year through 
a significant improvement of the virological surveillance system. 
Overall, 13.2% (n=1,874/14,212) were confirmed influenza cases, of which 70.2% 
(n=1,315/1,874) and 29.8% (n=559/1,874) were influenza A and B infections, respectively. 
As described in Table 2, roughly three quarters of identified influenza B cases (n=422/559) 
were from general population (community-based infections), sampled by family practitioners 
during outpatient visits, whereas 24.5% (n=137/559) were from hospitalized patients; no 
gender differences were found (data not shown). 
Influenza B infection was widely distributed between age-groups, with a clear predominance 
in children and teenagers; the median age was 9.0 years and, altogether, subjects aged ≤14 
years sustained more than 60% of total influenza B infections, recording the highest 
prevalence in age-group 5-9 years. 
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Community-based B infections were found in subjects substantially younger than hospitalized 
patients (median age, years: 8 vs. 51; p<0.001), and a comparison of age-stratified 
prevalences showed a significant inverse correlation between the two healthcare settings 
(Figure S1). 
Influenza B lineage information was collected during the entire study period. Basing on 
subtyping pooled data available from the two regions, Victoria-lineage viruses were more 
represented than those belonging to the Yamagata-lineage over the entire study period, 
accounting for 59.8% (n=298/498) and 40.2% (n=200/498) of cases, respectively (Table 3). 
On average, individuals infected with Victoria-lineage viruses were significantly younger 
than those presenting a Yamagata-lineage infection (median age, years: 8.0 vs. 12.0; 
p<0.001), reflecting the age-distribution observed among total B cases. 
Both influenza B lineages contributed to the 2010-2016 epidemics. Victoria-lineage strains 
predominated in the seasons 2010-2011 (77.1% vs. 22.9%) and 2015-2016 (97.4% vs. 2.6%), 
while in three consecutive seasonal outbreaks between 2012 and 2015, almost all infections 
were sustained by viruses belonging to the Yamagata-lineage. 
On the whole, according to the different population groups collected in the two regions, the 
proportion of influenza B found in the community was consistently higher than that observed 
among hospitalized patients. Nevertheless, the relative frequencies of the two lineages varied 
between healthcare settings, showing a wider spread of Victoria strains in the general 
population (63.9% vs. 36.1% for Victoria- and Yamagata-lineage, respectively), than that 
documented in ILI subjects with severe respiratory symptoms requiring an hospital admission 
(37.7% vs. 62.3% for Victoria- and Yamagata-lineage, respectively). In our study, a 
Yamagata-lineage infection represented an independent risk factor for a complicated 
influenza outcome (hospital-based vs. community-based management, OR=2.95; 95%CI: 1.78 
- 4.67). 
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Finally, for each season, the extent of lineage-level mismatch between influenza B strains 
circulating in our geographic areas and those included in vaccine formulation for the Northern 
Hemisphere was evaluated. 
During the six post pandemic seasons reported in the present study, the degree of mismatch 
was quite similar, when observed at the regional level. Pooled data depicted in Figure 2, 
documented a low degree of B mismatch in five consecutive seasons (range: 0-22.9%) 
between 2010 and 2015, while the circulation of B viruses belonging to the opposite lineage 
of the vaccine strain was exceptionally high (97.4%) during the last analysed season (2015-
2016). 
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DISCUSSION 
 
In this study, we analyzed the epidemiology and seasonal patterns of 559 influenza B 
infections identified among 14,212 subjects with ILI symptoms monitored during the 
surveillance seasons 2010-2016 in Liguria and Sicily, two Italian administrative regions 
located in the northern part and in the southern part of the country, where the influenza 
virological surveillance is seasonally performed as part of the national network (InfluNet). 
Our findings revealed that types A and B influenza viruses almost always co-circulated 
throughout the study period and confirmed the important role of influenza type B virus in the 
spread of infection in the population. 
On average, influenza B viruses accounted for 29.8% of total laboratory confirmed infections, 
and it was in the range of other European countries such as Finland [18] and UK [6,25]. In 
our setting, influenza B cases followed year-to-year fluctuations in prevalence and the highest 
value was observed in 2012-2013 (67.8%), a season characterized by a significant influenza B 
activity in the whole European region [26]. 
It has been widely highlighted the role of influenza disease as a determinant of excess 
mortality in the elderly [27-29], irrespective of genotype and subtype. 
On the other hand, children and adolescents have been shown to be crucial in the spread of the 
virus in the community, experiencing some of the highest rates of influenza infection during 
seasonal epidemics [18,30] and, in this regard, it has been suggested that influenza B viruses 
could be transmitted with a higher reproductive number (R0) in younger age population [31]. 
It is well known that influenza type B, when present as seasonal circulating virus within a 
geographic area, mainly occurs among younger persons than influenza A and school-aged 
children reflect the highest proportion of influenza B cases [18,19,25,32-34], as further 
confirmed in the present study among children aged 5-9 years. 
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In accordance, Harvala and colleagues [6] revealed higher rates of influenza B detections in 
Scottish children under the age of five years during the season 2012-2013, although a 
considerable circulation of B strains were also observed in adults. 
In Shanghai, the age distribution of B infections documented between 2009 and 2014 was 
higher among young outpatients (6-17 years) seeking hospital medical care for ILI [33], and 
similar findings were reported in a population study conducted in Southern China between 
2009 and 2010 [35]. 
Our results evidenced that ILI subjects infected by influenza B, in the context of the general 
population, were significantly younger than those admitted to hospital and an inverse 
correlation was found between the two healthcare settings, by comparison of age-stratified 
prevalences. Although, to our knowledge, no direct comparisons between the two population 
groups have been previously reported in the literature, studies conducted either in the general 
population [36] or in the hospital setting [6,35] highligthed, on average, an older age of 
patients in this latter group. According to other authors, no correlation was observed between 
influenza B infection and gender [34,37,38]. 
During the study period, different patterns of Yamagata- and Victoria-lineage B viruses were 
observed, albeit with similar trend between the two Italian regions. The distinct evolutionary 
viral variants of influenza B spread as single lineage or co-circulated among each season. 
The 2010-2011 influenza outbreak demonstrated the co-circulation of both B lineages in our 
geographic areas, but with the preponderance of Victoria-lineage viruses, and a similar 
scenario was depicted in Europe [39] and elsewhere worldwide, with the exception of China 
where Yamagata-lineage strains predominated [40]. Conversely, Victoria-lineage viruses 
were almost completely replaced by influenza strains belonging to the alternative lineage in 
the season 2012-2013, reflecting the trend obsderved in other European countries [6,41], as 
well as in the Southern Hemisphere [42]. Notably, a lineage swap was documented in Italy 
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since 2013 [43] and this epidemiological feature of B lineages was also evidenced in other 
countries such as Malaysia [44]. 
Moreover, an heterogenous distribution has been reported by age-group. Some authors from 
China and Malaysia as well as from Europe [35,38,44] revealed stark differences in age 
among B infected patients, reporting a trend towards a higher proportion of Victoria-lineage 
sustained infections in children and teenagers than those caused by either Yamagata-lineage 
viruses, suggesting an intrinsic different transmissibility of the two lineages [42]. 
Nevertheless, a limited variation in age susceptibility to different influenza B variants was 
found in Australia [36], while Mosnier and co-authors [34], in France, and Harvala and 
colleagues [6], in Scotland, did not find any relationship. 
In light of published data, the potential association between viral lineage and age of infected 
patients is still debated. It may be likely correlated with the local epidemiology of specific 
geographic region, as a result of a difference in background population immunity. 
Interestingly, Vijaykrishna and colleagues [42] recently proposed that age difference between 
Victoria- and Yamagata-lineage infections is thought to be due to differences in the molecular 
aspects of cellular dynamics which help the viruses to infect the epithelium of the respiratory 
tract, while more attractive hypotheses are consistent with a higher basic reproductive number 
(R0) of the Victoria-lineage viruses, which altogether might reduce the mean age of lineage-
specific infections. 
The distribution of Victoria- and Yamagata-lineage strains differed by healthcare setting. 
Victoria-lineage viruses were mostly responsible for a milder influenza disease in the general 
population, while a greater proportion of infections detected in hospital were sustained by 
viruses belonging to the Yamagata-lineage. Of note, this was not biased by age, suggesting 
that Yamagata-lineage viruses on average could be responsible of more complicated 
infections. However, the limited number of patients with these characteristics in our dataset 
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and the potential bias due to the different population characteristics and surveillance systems 
in the two regions prevent us from drawing conclusions. 
Finally, our findings evidenced that the level of B vaccine mismatch varied during the six 
seasons, with the highest impact observed in 2015-2016. 
In a study by Heikkinen et al (2014) conducted in Finland, a similar proportion of lineage-
level mismatched B viruses was observed, although over a different time slot that partially 
overlapped our study period; in Australia, a mismatch >60% occurred in over one-third 
seasons between 2001 and 2014 [36], while a 10-year influenza surveillance conducted in 
Northern Italy [23] highlighted the occurrence of B vaccine mismatch in five seasons between 
2004 and 2014. 
The potential impact of vaccine-mismatch on influenza virus epidemiology has been broadly 
investigated and several findings highlighted the effect of seasonal vaccine mismatch on 
influenza epidemiology, particularly among those age-groups that preferentially sustain the 
circulation of influenza B virus. The lack of availability of vaccination data in our study 
population limit our possibility to draw any inference on this topic. However, as reported by 
other authors, the magnitude of the impact of seasonal vaccine mismatch on influenza 
epidemiology depends on several factors, including the annual effectiveness of the vaccine 
and the annual population vaccine coverage, but also on factors such as the overall burden of 
influenza during a given season and the proportion of each influenza B virus lineage 
circulating [28]. 
On the basis of the results shown in this and other studies, it is evident how much important 
could be the impact of B vaccine mismatch in terms of efficacy of trivalent influenza vaccines 
in general population, given the global impact of influenza B, the undemonstrated cross-
reactivity of trivalent vaccines against the two influenza B lineages and, more importantly, the 
unability to predict the seasonal epidemiology of influenza viruses. It seems quite clear that 
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the real-life efficacy of influenza vaccines could be significant improved by a broader 
adoption of quadrivalent formulations, expecially in children [18,28,45]. 
Furthermore, it seems a logical consequence that children and adolescents might benefit most 
from the implementation of specific vaccine-based preventive measures, which may have the 
potential to reduce the burden of disease in both vaccinated and unvaccinated individuals. 
Additionally, benefits may also include contraction in absenteeism due to the need for parents 
to take time of work to care for sick children [46,47] and reduced pressure on health care 
services during seasonal peak in influenza activity [48,49]. 
Nevertheless, despite previous assumptions, only USA and Canada among large developed 
countries, and some rare exceptions in Europe such as Finland, Latvia and United Kingdom, 
actually recommend the influenza vaccination of healthy children providing the vaccine free 
of charge [50]. 
Resistance to implementing vaccination programmes on healthy children may found possible 
explanations in the limited evidence for the field efficacy of inactivated and live attenuated 
vaccines in younger children, among whom the risk of complication is the greatest [51,52], 
the level of uptake which programmes would be able to achieve [53], and the additional 
resources required to expand seasonal influenza vaccination campaigns. 
Of course this study suffer of some limitations. First, only two Italian regions were included 
in the virological surveillance campaign and the formal representativeness of this population 
is unknown. Moreover, different population settings, either from the Northern part or the 
Southern part of Italy, contributed to the population study and this may have locally biased 
the results. However, basing on the reports from the National surveillance network, we are 
reasonably confident that, on average, our settings have adequately represented the 
epidemiology and burden of influenza B strains in Liguria and Sicily during the six seasons 
studied. 
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The unpredictability of influenza viruses continues to represent a major challenge to health 
systems. Nevertheless, vaccination remains the most effective preventive measure in reducing 
the incidence and severity of disease, although the coverage rates in Italy [54] and other 
European countries [55] remain suboptimal. In particular, during the study period, coverage 
rates for influenza vaccination decreased at Italian level from 62.4% to 49.9% and from 
17.9% to 13.9% in subjects aged ≥65 years and in general population, respectively, and a 
similar trend was registered in the two considered Italian regions [54]. 
The increased use of childhood vaccination is an opportunity for reducing the considerable 
burden of infection in this age group and it may play a pivotal role in the spread of the virus 
in the community, also supported by the adoption of quadrivalent vaccines in universal 
immunization programmes against influenza. 
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MATERIALS AND METHODS 
 
Case definition 
The enrollment criteria for surveillance cases were in accordance to the operative protocol of 
the Italian Influenza Epidemiological and Virological Surveillance Network [56]. A case of 
ILI was defined as one individual with sudden onset of at least one of the following systemic 
symptoms: fever (≥37.5°C), general discomfort or asthenia, headache, muscle pain, and at 
least one of the respiratory symptoms between cough, sore throat, and shortness of breath. 
 
Study population and retrospective data collection 
We analysed all available clinical and virological data, collected during six consecutive post-
pandemic influenza seasons over the period 2010-2016, from week 42 to week 17 of the 
following year, in two different Italian administrative regions located in the South (Sicily) and 
in the North (Liguria) of the country, where two regional reference laboratories for the 
influenza surveillance belonging to the InfluNet have been active for all the study period. 
All surveillance data are aggregated at a regional level, shared at a national level on a weekly 
basis, and ultimately flow into the World Health Organization's (WHO) global influenza 
programme. 
Each year, a number of paediatricians and general practitioners contribute to the community-
based influenza surveillance, while both paediatric and adult hospitals allow the monitoring of 
ILI patients admitted with severe respiratory distress, potentially correlated to influenza 
infection. 
More specifically, the Ligurian influenza surveillance system essentially collected data from 
both hospital inpatients and outpatients (99.0%; n=11,008/11,120), while the influenza 
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virological surveillance in Sicily resulted mostly oriented to general population (70.2%; 
n=2,172/3,092). 
Anonymised data on birthdate, sex, date of ILI onset, outcomes were gathered from each ILI 
cases. 
 
Routine testing and influenza virus genotyping 
Oropharyngeal samples were obtained from each patient and transported to the regional 
reference laboratories by using Virocult swabs (MWE, Medical Wire). 
Viral RNA was extracted using QIAamp Viral RNA extraction kit (QIAGEN) according to 
the manufacturer's suggested protocol and the RNA was eluted from the spin column in 60 μL 
of elution buffer. Eluted RNA was divided into aliquots and stored immediately at -80°C until 
further use. Each sample was tested by one-step real-time RT-PCR for the presence of 
influenza virus RNA (protocols available on request), and influenza B positive samples were 
genotyped using lineage-specific multiplex one-step real-time RT-PCR according the "WHO 
protocols for molecular diagnosis of influenza virus" [57] using a QuantStudio 7 Flex Real-
Time PCR system (Applied Biosystem). 
 
Seasonal mismatch with trivalent vaccine B lineage 
Data on the circulation of different lineages of influenza B viruses in Sicily and Liguria were 
retrieved during each season. 
The extent of vaccine mismatch against influenza B viruses was estimated by comparing the 
information concerning the B lineage antigens contained in the trivalent vaccine for the 
Northern Hemisphere, as recommended by the WHO, and the proportion of circulating B 
viruses belonging to different lineages. 
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The level of B vaccine mismatch was defined as the percentage ratio between the proportions 
of mismatched and matched influenza B viruses per year of surveillance. 
 
Data managements and statistical analysis 
Descriptive statistics were used to summarize each of the socio-demographic and clinical 
variables included in the dataset (counts, percentages, median and interquartile range, as 
appropriate). 
The study population was arbitrarily subdivided into nine different age groups, categorizing 
children/teenagers into four groups (≤4, 5-9, 10-14, and 15-19 years) and adults/elderly into 
five groups (20-34, 35-49, 50-64, 65-85, and >85 years). 
Median values were compared using the Mann-Whitney U test. All of the analyses with p-
values of 0.05 or less were considered to be statistically significant (two tailed). Data were 
processed with the STATA MP statistical software package v14.1 for Apple™ (StataCorp). 
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Table 1. Number of specimens tested, influenza cases, and relative percentages attributable to influenza A and B virus 
subtypes. Period: 2010-2016 
 
Influenza season 
ILI incidence 
rate (x 1,000) 
* 
Number of 
specimens 
tested 
Influenza cases Influenza A Influenza B 
Total [n (%), % by 
row] 
 14,212 1,874 (13.2) 1,315 (70.2) 559 (29.8) 
2010-2011 11.1 2,228 273 (12.2) 210 (76.9) 63 (23.1) 
2011-2012 9.6 1,658 192 (11.6) 192 (100.0) 0 
2012-2013 10.0 1,961 227 (11.6) 73 (32.2) 154 (67.8) 
2013-2014 6.6 2,234 162 (7.2) 159 (98.1) 3 (1.9) 
2014-2015 10.9 2,705 335 (12.4) 270 (80.6) 65 (19.4) 
2015-2016 6.1 3,426 685 (20.0) 411 (60.0) 274 (40.0) 
 
* National influenza-like illness (ILI) incidence rate at the epidemic peak. Source: InfluNet, influenza sentinel surveillance 
network, Italy. 
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Table 2. Age distribution of influenza B infections, according to community and hospital settings. Period: 2010-2016. 
 
 
Influenza B infections 
Total 
[n (%)] 
Community-based 
[n (%)] 
Hospital-based 
[n (%)] 
 559 422 (75.5) 137 (24.5) 
Age (years) [median (IQR)] 9.0 (33) 8.0 (8)* 51.0 (48)* 
 Age groups (years) [n (%), % by column]    
 ≤4 98 (17.5) 85 (20.1) 13 (9.5) 
 5-9 182 (32.6) 172 (40.8) 10 (7.3) 
 10-14 66 (11.8) 61 (14.4) 5 (3.6) 
 15-19 24 (4.3) 21 (5.0) 3 (2.2) 
 20-34 38 (6.8) 23 (5.4) 15 (11.0) 
 35-49 46 (8.2) 26 (6.2) 20 (14.7) 
 50-64 46 (8.2) 18 (4.3) 28 (20.4) 
 65-85 53 (9.5) 15 (3.6) 38 (27.7) 
 >85 6 (1.1) 1 (0.2) 5 (3.6) 
 
* p<0.001 
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Table 3. Proportion of influenza B infections, according to viral lineage (pooled data from Liguria and Sicily). Period 2010-
2016. 
 
 Victoria-lineage Yamagata-lineage 
Influenza B infections [n (%), % by row], n=498 298 (59.8) 200 (40.2) 
Age (years) [median (IQR)] 8.0 (9.0)* 12.0 (40.0)* 
 Age groups (years) [n (%), % by column]   
 ≤4 57 (19.1) 32 (16.0) 
 5-9 124 (41.6) 54 (27.0) 
 10-14 44 (14.8) 20 (10.0) 
 15-19 13 (4.3) 10 (5.0) 
 20-34 20 (6.7) 11 (5.5) 
 35-49 10 (3.4) 27 (13.5) 
 50-64 10 (3.4) 25 (12.5) 
 65-85 20 (6.7) 15 (7.5) 
 >85 0 6 (3.0) 
Influenza season [n (%), % by row]   
 2010-2011 27 (77.1) 8 (22.9) 
 2011-2012 0 0 
 2012-2013 5 (3.9) 122 (96.1) 
 2013-2014 0 1 (100.0) 
 2014-2015 0 62 (100.0) 
 2015-2016 266 (97.4) 7 (2.6) 
Healthcare settings [n (%), % by row]Δ   
 Community-based 269 (63.9) 152 (36.1) 
 Hospital-based 29 (37.7) 48 (62.3) 
 
* p<0.001 
Δ OR=2.95 (95%CI: 1.78 - 4.67). Hospital-based setting as reference group. 
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FIGURE CAPTIONS 
 
Figure 1. Prevalence of confirmed influenza A and B infections between 2010 and 2016, 
according to annual epidemic. 
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Figure 2. Relative frequencies of lineage-level matched and mismatched influenza B virus 
infections identified between 2010 and 2016, compared with the vaccine strain for 
the Northern Hemisphere and according to annual epidemic (pooled data from 
Liguria and Sicily). 
 
